BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 28.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,132,377 shares of the biotechnology company’s stock after selling 451,829 shares during the period. JPMorgan Chase & Co. owned approximately 0.54% of BioCryst Pharmaceuticals worth $8,595,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. CIBC Bancorp USA Inc. acquired a new position in shares of BioCryst Pharmaceuticals during the third quarter valued at $169,000. Voleon Capital Management LP bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter valued at about $816,000. Verition Fund Management LLC lifted its holdings in BioCryst Pharmaceuticals by 162.4% in the third quarter. Verition Fund Management LLC now owns 57,451 shares of the biotechnology company’s stock worth $436,000 after purchasing an additional 35,555 shares during the period. Sherbrooke Park Advisers LLC grew its position in BioCryst Pharmaceuticals by 30.5% in the 3rd quarter. Sherbrooke Park Advisers LLC now owns 16,524 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 3,866 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its position in BioCryst Pharmaceuticals by 1.6% in the 3rd quarter. Qube Research & Technologies Ltd now owns 2,410,362 shares of the biotechnology company’s stock valued at $18,295,000 after buying an additional 36,873 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on BCRX shares. Weiss Ratings upgraded shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Wednesday, March 4th. HC Wainwright increased their price objective on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 15th. Royal Bank Of Canada lowered their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Finally, Evercore assumed coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 target price on the stock. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $19.64.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock opened at $9.33 on Monday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.31. The stock has a market cap of $2.34 billion, a PE ratio of 7.78 and a beta of 0.73. The company’s 50-day moving average price is $7.77 and its two-hundred day moving average price is $7.48.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.07 by $1.05. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The company had revenue of $163.28 million during the quarter, compared to analyst estimates of $151.32 million. During the same quarter last year, the firm posted ($0.13) EPS. The business’s revenue for the quarter was up 209.1% on a year-over-year basis. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 150,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the transaction, the insider owned 400,703 shares in the company, valued at approximately $3,666,432.45. The trade was a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 5.10% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.